释放潜力:癌症治疗中的受体介导向药物递送
Balaji Palanisamy1, Abul Kalam Azad Mandal1
1Department of Biotechnology, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India.
Pathology, research and practice
|April 10, 2025
概括
受体向药物递送提供了精确的癌症治疗,通过向特定的受体,最大限度地减少副作用. 这种方法提高了治疗效率,并有助于诊断和监测,以获得更好的患者结果.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 生物技术是生物技术.
背景情况:
- 受体介导的向药物递送是癌症治疗的关键策略.
- 受体在癌症的进展,转移中起着至关重要的作用,并作为治疗点.
研究的目的:
- 审查受体在癌症生物学中的作用及其治疗潜力.
- 探索受体向药物递送系统和策略的进展.
- 讨论受体向癌症治疗的挑战和未来方向.
主要方法:
- 在癌症治疗中受体介导的向药物递送的文献综述.
- 基于联体的向方法 (小分子,,抗体) 的分析.
- 研究工程纳米粒子,双重准策略和TME交付.
主要成果:
- 受体向提高了特异性,减少了癌症治疗中的全身毒性.
- 新型配体和工程纳米粒子提高了药物输送效率.
- 向瘤微环境和转移性位显示有望提高疗效.
- 针对受体的成像技术有助于诊断和治疗监测.
结论:
- 针对受体的策略代表了癌症治疗的重大进展.
- 需要进一步的研究和跨学科的合作来优化这些方法.
- 本综述为开发更有效的基于受体的癌症治疗提供了路线图.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Targets for Drug Action: Overview
5.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
5.9K
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K


